scholarly article | Q13442814 |
P356 | DOI | 10.1185/030079907X210615 |
P698 | PubMed publication ID | 17588306 |
P50 | author | Eric Q Wu | Q67190782 |
P2093 | author name string | Lei Chen | |
Elaine Yang | |||
Howard Birnbaum | |||
Mary Cifaldi | |||
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | rheumatoid arthritis | Q187255 |
P304 | page(s) | 1749-1759 | |
P577 | publication date | 2007-08-01 | |
P1433 | published in | Current Medical Research and Opinion | Q5195063 |
P1476 | title | Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data | |
P478 | volume | 23 |
Q46638150 | Applying Value-Based Insurance Design To High-Cost Health Services |
Q36439036 | Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspective |
Q37992954 | Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis |
Q43461275 | Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey |
Q59822850 | Do COX-2 inhibitors provide additional pain relief and anti-inflammatory effects in patients with rheumatoid arthritis who are on biological disease-modifying anti-rheumatic drugs and/or corticosteroids? Post-hoc analyses from a randomized clinical t |
Q36274355 | Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis |
Q34311262 | Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data |
Q47188529 | Medical Care Costs Associated with Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta-analysis. |
Q38067449 | Similar biotherapeutic products: overview and reflections |
Q35205411 | The economic burden of TNFα inhibitors and other biologic treatments in Norway |
Q43194443 | The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients |
Q84565204 | The importance of clinical variables in comparative analyses using propensity-score matching: the case of ESA costs for the treatment of chemotherapy-induced anaemia |
Q38062338 | Treatment costs of attention deficit hyperactivity disorder in Germany |
Q36923598 | Tumor necrosis factor-blocker dose escalation in rheumatoid arthritis patients in a pharmacy benefit management setting |
Q37000165 | Use of biologics in rheumatoid arthritis: current and emerging paradigms of care |
Search more.